March's top retina news

New technologies and treatments to regain sight, including the first gene therapy procedure performed since its FDA approval, were among the topics of the most popular retina/vitreous-related articles on Healio.com/OSN in March.

Here are the five most-read retina articles of the month:

Prefilled anti-VEGF injection may reduce risk of endophthalmitis

Mounting evidence from an ongoing multicenter collaboration demonstrates that anti-VEGF injection via prefilled syringe may substantially reduce the risk of endophthalmitis compared with the conventional method of injection, Philip Storey, MD, MPH, said at the Wills Eye Conference. Read more.

Patients regain sight after treatment with retinal tissue from stem cells

Patients with sudden severe sight loss from wet AMD have regained reading vision after being implanted with an engineered patch of retinal pigment epithelium cells derived from stem cells. Read more.

Lucentis 0.3 mg prefilled syringe approved by FDA for all forms of diabetic retinopathy

Genentech announced the FDA approved the Lucentis 0.3 mg prefilled syringe to treat diabetic retinopathy with or without diabetic macular edema. The 0.3 mg prefilled syringe is expected to be available in the second quarter of this year. Read more.

First gene therapy procedure for inherited retinal disease performed

A clinician-scientist from Massachusetts Eye and Ear performed the first Luxturna gene therapy treatment since its FDA approval in December. Read more.

Eylea meets first endpoint in phase 3 nonproliferative diabetic retinopathy trial

The phase 3 PANORAMA trial of Eylea in patients with moderately severe to severe nonproliferative diabetic retinopathy met its 24-week endpoint. Read more.